BCL2 and neoplasm: Since IL-8 is able to inhibit not only apoptosis-inducing proteins caspase 3 and 9, but also PARP, and promotes the expression of Bcl-2, Survivin or Bcl-xl, -xs [32,33,34]; tumor-associated enhanced IL-8 may directly counteract apoptosis and ICI therapy response.